Ara-290vsTB-500

Ara-290 is an 11-amino-acid peptide designed to selectively activate the innate repair receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131/βcR). This receptor is distinct from the classical homodimeric EPOR that mediates erythropoiesis, which is why Ara-290 can deliver tissue-protective effects without stimulating red blood cell production or the thrombotic risks associated with EPO.

The IRR is expressed on tissues subjected to metabolic stress, inflammation, or injury — including neurons, Schwann cells, cardiomyocytes, renal tubular cells, and endothelial cells. When Ara-290 activates the IRR, it triggers a cascade of protective signaling pathways: JAK2/STAT5 activation promotes anti-apoptotic gene expression (Bcl-2, Bcl-xL); PI3K/Akt signaling provides cell survival signals; NF-κB modulation shifts the inflammatory balance from pro-inflammatory to pro-resolution. The net effect is protection of viable cells from death, reduction of inflammation, and activation of repair processes.

Ara-290's most clinically advanced application is in peripheral neuropathy, particularly diabetic small fiber neuropathy. Schwann cells — the myelinating glial cells of the peripheral nervous system — express the IRR, and Ara-290 stimulates their survival and regenerative capacity. In clinical trials, subcutaneous Ara-290 administration improved corneal nerve fiber density (a measure of small fiber regeneration) and reduced neuropathic symptoms. Despite its extremely short plasma half-life (approximately 2 minutes), the tissue-protective effects persist for days because the cellular signaling cascades activated by IRR engagement have sustained downstream effects that outlast the peptide's presence in circulation.

TB-500 is the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide present in virtually every nucleated cell in the body. Its central molecular function is the sequestration of G-actin monomers — the globular, unpolymerized form of actin. By binding G-actin at a 1:1 ratio, TB-500 maintains a reservoir of monomeric actin that can be rapidly mobilized for polymerization into F-actin filaments when cells need to migrate, change shape, or form new structures during tissue repair.

This actin-regulating role is fundamental to TB-500's healing effects. When tissue is damaged, cells at the wound margin must migrate into the injury site. Cell migration requires dynamic actin polymerization at the leading edge of the cell (forming lamellipodia and filopodia) and depolymerization at the trailing edge. TB-500 facilitates this process by providing a controlled supply of G-actin monomers. It promotes migration of keratinocytes (for skin wound closure), endothelial cells (for new blood vessel formation), and cardiac progenitor cells (for heart repair).

Beyond actin regulation, TB-500 has significant anti-inflammatory and gene-regulatory effects. It downregulates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α while upregulating anti-inflammatory mediators. It activates cell survival pathways, specifically Akt-mediated anti-apoptotic signaling, protecting damaged cells from programmed cell death. TB-500 also promotes angiogenesis by stimulating endothelial progenitor cell differentiation and new capillary formation. In cardiac tissue, it has demonstrated the ability to activate epicardial progenitor cells and promote cardiomyocyte survival following ischemic injury. The combination of cell migration, anti-inflammation, angiogenesis, and cell survival makes TB-500 one of the most broad-spectrum healing peptides available.